RE:RE:RE:RE:RE:Disapointed and mostly in the dark.Sorry. 300 mg/m2 is only 30% higher dose than the MTD of docetaxel alone. Releasing this info without efficacy data to back a proof of concept is very scary to me. For somebody like me who understands enogh of the science, it's the worst case scenario. On one hand you worry a lot, because 300 mg/m2 is so low of a MTD. It is so close to the MTD of docetaxel alone that it could be the sign that this PDC is not working in humans. On the other hand, they talk like all is fine and that they will go forward with that dose, showing no dispointment, which is very strange, unless they already have efficacy data and proof of concept. But today, they dropped only the very low MTD, that is not even confirmed, and not a proof of concept to go along with it, and would make sense of the whole thing. So it comes down to faith in the company, which to this point was, in the end, never warranted.
SPCEO1 wrote: My Base Case Scenario was for the 420mg dose to be the MTD, so I am disappointed with that as well. But I am also pretty happy about the 300mg dose, so I am not that disappointed. We are mostly in the dark about the trial and I think that is because the trial has actually been pretty messy behind the scenes. To go on this long it had to have some real twists and turns in it and there is no way TH is going to share such details with us. We will get to hear what they want us to hear and nothing more especially since another financing is on the horizon. Still, in the end, 300mg is going to deliver a whole lot of Docetaxel to cancer cells assuming TH is able to show that the drug works as designed. In fact, it may in the end be a better dose to use long term as it may allow for a very long period of treatment and considerable extension of a patient's life. Even a lower dose would still not be a disaster if the drug actually does work as intended as it will still get much more Docetaxel into the cancer cells than a normal dose of Docetaxel would. So, while backing away from 420mg was not what we were hoping for, it is hardly the end of the world. When they soon share with us the final details of the trial and turn the light on at least the positive data from it, I suspect we will still be pretty happy with TH's prospects in cancer. And they also did expand the number of cancers they are targetting, giving TH more shots on goal to have a successful result. So, it was hardly all disappointing news. Finally, I have to assume the potential Chinese partners are getting a better look at the data than we are and apparently many are still interested. That is a good sign that whatever TH has does have merit.
jfm1330 wrote: The phase Ia is at the worst case scenario level that is not a plain failure. I hate the study design mixing all kind of sortilin expression levels. They have data that we don't have, and it frustrates me. We are mostly in the dark about what is going on, except to now know that 300 mg/m2 is the best possible MTD we can expect. The problem, is that it is also the lowest possible significative MTD. I was expecting 420 mg/m2 as the minimal MTD. Now it's much lower than that. This is the main negative news we learned today.
jfm1330 wrote: SPCEO1 wrote: What changed today from your perspective and how did it lead you to be " mostly in the dark"?
As you have pointed out, and I agree, most everything positive for the stock depends upon a good result for the phase 1 trial. It looks like we will have to wait another 2-3 months to get the facts you are looking for.
jfm1330 wrote: I listen to the call. If you have a realistic and positive scenario based on facts, not wishful thinking, put it forward clearly because personally I don't see it. Again, no rose-colored glasses. I want something based on facts that would lead you to think that this stock will go up in the next year. Again, no wishful thinking. FACTS!!!